Tags

Type your tag names separated by a space and hit enter

Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Vasc Health Risk Manag. 2007; 3(2):181-90.VH

Abstract

The endocannabinoid system (ECS) is an endogenous physiological system composed of two cannabinoid receptors and several endogenous ligands. The ECS is intimately involved in appetite regulation and energy homeostasis, which makes it an intriguing target for pharmacological treatment of obesity, diabetes, and the metabolic syndrome. Rimonabant is the first cannabinoid receptor (CB-1) antagonist being studied and utilized to treat obesity (it is approved in Europe but is currently under review in the United States). Large randomized trials with rimonabant have demonstrated efficacy in treatment of overweight and obese individuals with weight loss significantly greater than a reduced calorie diet alone. In addition, multiple other cardiometabolic parameters were improved in the treatment groups including increased levels of high density lipoprotein cholesterol, reduced triglycerides, reduced waist circumference, improved insulin sensitivity, decreased insulin levels, and in diabetic patients improvement in glycosylated hemoglobin percentage. There was an increase in the adverse effects of depression, anxiety, irritability, and nausea in rimonabant-treated groups. This novel medication may become an important therapeutic option in the fight to reduce cardiovascular disease worldwide through its unique action on cardiometabolic risk.

Authors+Show Affiliations

Division of General Internal Medicine, Department of Medicine, University of Nevada School of Medicine, Reno, NV 89557, USA. kbronander@medicine.nevada.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17580728

Citation

Bronander, Kirk A., and Michael J. Bloch. "Potential Role of the Endocannabinoid Receptor Antagonist Rimonabant in the Management of Cardiometabolic Risk: a Narrative Review of Available Data." Vascular Health and Risk Management, vol. 3, no. 2, 2007, pp. 181-90.
Bronander KA, Bloch MJ. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vasc Health Risk Manag. 2007;3(2):181-90.
Bronander, K. A., & Bloch, M. J. (2007). Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vascular Health and Risk Management, 3(2), 181-90.
Bronander KA, Bloch MJ. Potential Role of the Endocannabinoid Receptor Antagonist Rimonabant in the Management of Cardiometabolic Risk: a Narrative Review of Available Data. Vasc Health Risk Manag. 2007;3(2):181-90. PubMed PMID: 17580728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. AU - Bronander,Kirk A, AU - Bloch,Michael J, PY - 2007/6/22/pubmed PY - 2007/8/23/medline PY - 2007/6/22/entrez SP - 181 EP - 90 JF - Vascular health and risk management JO - Vasc Health Risk Manag VL - 3 IS - 2 N2 - The endocannabinoid system (ECS) is an endogenous physiological system composed of two cannabinoid receptors and several endogenous ligands. The ECS is intimately involved in appetite regulation and energy homeostasis, which makes it an intriguing target for pharmacological treatment of obesity, diabetes, and the metabolic syndrome. Rimonabant is the first cannabinoid receptor (CB-1) antagonist being studied and utilized to treat obesity (it is approved in Europe but is currently under review in the United States). Large randomized trials with rimonabant have demonstrated efficacy in treatment of overweight and obese individuals with weight loss significantly greater than a reduced calorie diet alone. In addition, multiple other cardiometabolic parameters were improved in the treatment groups including increased levels of high density lipoprotein cholesterol, reduced triglycerides, reduced waist circumference, improved insulin sensitivity, decreased insulin levels, and in diabetic patients improvement in glycosylated hemoglobin percentage. There was an increase in the adverse effects of depression, anxiety, irritability, and nausea in rimonabant-treated groups. This novel medication may become an important therapeutic option in the fight to reduce cardiovascular disease worldwide through its unique action on cardiometabolic risk. SN - 1176-6344 UR - https://www.unboundmedicine.com/medline/citation/17580728/Potential_role_of_the_endocannabinoid_receptor_antagonist_rimonabant_in_the_management_of_cardiometabolic_risk:_a_narrative_review_of_available_data_ L2 - https://www.dovepress.com/articles.php?article_id=1480 DB - PRIME DP - Unbound Medicine ER -